Around 95% of oncology drugs fail during clinical development. Every tumour is different, and predicting which treatments will actually work in patients remains one of the industry's biggest challenges.
Orakl combines AI with real patient biology, growing patient-derived tumour cells in the lab to test how they respond to treatments. Its AI has demonstrated 90% accuracy in predicting cancer clinical trial outcomes, helping pharma identify the most promising drugs years before they reach the clinic.
Around 95% of oncology drugs fail during clinical development. Every tumour is different, and predicting which treatments will actually work in patients remains one of the industry's biggest challenges.
Orakl combines AI with real patient biology, growing patient-derived tumour cells in the lab to test how they respond to treatments. Its AI has demonstrated 90% accuracy in predicting cancer clinical trial outcomes, helping pharma identify the most promising drugs years before they reach the clinic.
Explore companies within the same category